Eli Lilly shares jump 7% as pharma giant raises 2026 outlook

Eli Lilly's shares rose 5% after Q3 revenue increased 39% to $24.4B, beating estimates. The company raised 2026 revenue guidance by $5.5B. Mounjaro and Zepbound sales grew 65% and 49%, respectively. Gross margin improved to 83.9%, but one-time benefits and deal charges impacted EPS guidance.

Eli Lilly reported Q3 2026 revenue of $24.5B, up 39% YoY, and raised full-year guidance to $91-92B. Mounjaro and Zepbound combined for $16B in revenue. CEO Dave Ricks cited strong growth in new pharmaceutical categories. Non-GAAP EPS was $7.48, including $4.57 in acquired R&D charges. The company expects continued volume growth but notes 2026 benefited from $2B in one-time items.

Eli Lilly's shares hit a record high after strong Q3 earnings, driven by obesity drug sales. The company raised its full-year revenue forecast, adding $80B to its market cap. Analysts praised its performance and growth prospects, with Kisunla sales exceeding estimates.

Eli Lilly raised its full-year revenue guidance to $91-92B, up $10B, due to strong GLP-1 sales. CEO David Ricks attributed the increase to unprecedented market expansion and the Medicare GLP-1 Bridge program. Q3 revenue rose 39% to $24.4B. Lilly is also investing in early-stage deals across therapeutic categories.

Eli Lilly raised guidance again due to strong weight-loss drug sales, with third-quarter Kisunla sales at $193M, above estimates. BMO warns of potential investor scrutiny if Foundayo's launch underperforms. Guggenheim highlights strength in cardiometabolic medicines. Repeated guidance raises may increase stock volatility.

Eli Lilly's market cap hit $1.3T for the first time after Q3 revenue rose 39% YoY to $24.4B, net profit up 16% to $6.45B. The company raised full-year 2026 revenue guidance to $91B-$92B. Shares surged 7.19% to $1,380.95.